Allen H. Mackenzie, M.D.; J. E. Nousek, M.D.; A. L. Scherbel, M.D., F.A.C.P.; M. Atdjian, M.D.
Mackenzie AH, Nousek JE, Scherbel AL, Atdjian M. Ocular Changes in Rheumatoid Arthritis: Comparison of Patients Treated with and without Antimalarial Drugs.. Ann Intern Med. 1964;61:796. doi: 10.7326/0003-4819-61-4-796_2
Download citation file:
Published: Ann Intern Med. 1964;61(4):796.
This content is PDF only. Please click on the PDF icon to access.
Recent reports on ocular toxicity of chloroquine emphasize the frequent occurrence of keratopathy and retinopathy. The incidence and severity of lesions vary greatly in these reports. Our experience with 300 patients shows ocular toxicity to be uncommon, and serious lesions are rare.
Serial ophthalmologic examinations were done in 300 patients having rheumatoid disease treated with chloroquine (250 mg/day) or hydroxychloroquine (400 mg/day). Median duration of therapy is 3.5 years.
Chloroquine keratopathy was present in 10% of patients. These deposits are benign and regress when therapy ceases. No patient developed typical bullseye disciform chloroquine retinopthy in this series. No visual impairment
Learn more about subscription options.
Register Now for a free account.
Rheumatoid Arthritis, Rheumatology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only